Disease Overview：Progressive Supranuclear Palsy（PSP）
Progressive supranuclear palsy (PSP) is a rare, progressive neurodegenerative disorder characterized by tau protein accumulation in basal ganglia, brainstem, and cortical regions. Clinically, it manifests with early postural instability, vertical supranuclear gaze palsy—particularly impaired downward saccades—bradykinesia, axial rigidity, cognitive decline (especially executive dysfunction), and pseudobulbar affect. Unlike Parkinson’s disease, PSP shows poor or transient response to levodopa and lacks resting tremor. Diagnosis relies on clinical criteria (e.g., MDS-PSP criteria), supported by MRI showing midbrain atrophy (“hummingbird” or “penguin sign”), DaT-SPECT to differentiate from parkinsonian syndromes, and increasingly, CSF biomarkers and tau-PET imaging. There is no disease-modifying therapy; management remains symptomatic—multidisciplinary rehabilitation, speech-language pathology for dysphagia, and pharmacologic support for mood and behavioral symptoms.
China offers distinct advantages for PSP care: leading neurology centers—including Beijing Tiantan Hospital and Shanghai Huashan Hospital—host specialized movement disorders units with deep expertise in atypical parkinsonism diagnostics and longitudinal symptom management. Advanced infrastructure includes 3T MRI with quantitative volumetry, high-resolution diffusion tensor imaging, and centralized tau biomarker research platforms. Real-world outcomes reflect improved functional stabilization and reduced aspiration-related hospitalizations through integrated neurorehabilitation protocols. Treatment costs are typically 40–60% lower than in the US or EU, without compromising diagnostic rigor or therapeutic continuity. As a medical tourism agency, we facilitate seamless international patient journeys—pre-arrival clinical coordination, transparent itemized pricing, visa assistance, interpreter services, and post-discharge tele-neurology follow-up—ensuring continuity of care grounded in evidence-based practice.
Progressive Supranuclear Palsy: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Progressive Supranuclear Palsy (PSP)
Non-Surgical / Conservative / Medication Management
*Target Criteria:* Early-moderate PSP (NINDS–MDS criteria), preserved swallowing function, no severe autonomic instability.
- •Symptomatic Pharmacotherapy
- Amantadine (off-label): ¥90–¥260/month ($13–$37) - SSRIs (e.g., sertraline) for apathy/depression: ¥80–¥220/month ($11–$31)
- •Multidisciplinary Rehabilitation
- Speech-language therapy (dysarthria/swallowing safety): ¥1,800 ($255) - Occupational therapy (ADL adaptation): ¥1,500 ($212)
- •Diagnostic & Monitoring Fees
- CSF biomarker panel (Aβ42, p-tau, total tau): ¥1,650 ($233) - Annual neuropsychological battery (MoCA, FAB, SDMT): ¥620 ($88)
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Severe dysphagia with recurrent aspiration pneumonia (>2 episodes/year); confirmed videofluoroscopic swallow study (VFSS) showing aspiration; no dementia stage ≥MMSE <18; stable cardiac/respiratory status.
- •Percutaneous Endoscopic Gastrostomy (PEG)
- Preoperative workup (ECG, chest X-ray, coagulation panel, VFSS): ¥1,350 ($191) - Post-procedure nursing & tube maintenance (3 months): ¥2,100 ($297)
- •Deep Brain Stimulation (DBS)
Special / Complex Condition Management
- •Advanced Dysphagia with Tracheostomy Dependence
- •Severe Autonomic Dysfunction (orthostatic hypotension, urinary retention)
- •Palliative Home Care Program (Grade 3A hospital-affiliated)
Quick Selection Guide
- •Age <65, Mild Gait Instability, Budget-Conscious: Start with levodopa trial + PT ($340) + MRI ($110). Total Year 1: ~$550.
- •Age 65–75, Moderate Falls & Dysphagia, Moderate Budget: Add SLP + PEG evaluation ($191) → proceed to PEG if indicated ($1,550–$2,260 total Year 1).
- •Age >75, Severe Disability + Aspiration Pneumonia History, High Comorbidity Burden: Prioritize palliative home care + tracheostomy support ($2,450–$4,140 Year 1) — avoids high-risk interventions.
- •All Patients: Mandatory annual CSF biomarkers ($233) to exclude mimics (e.g., corticobasal degeneration) and guide prognosis.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Progressive Supranuclear Palsy Medical Vacation Packages
Curated transparent all-inclusive packages combining Progressive Supranuclear Palsy treatment with China top medical destinations:
